Patent · US Active

2,4-pyrimidinediamine compounds and their uses

US8822685B2 · kind B2 · utility

43Cited by

6References

17Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Rajinder Singh · Belmont, US
Ankush Argade · Foster City, US
Donald Payan · Hillsborough, US
Susan Molineaux · San Francisco, US
Sacha Holland · San Francisco, US
Jeffrey Clough · Redwood City, US
Holger Keim · Irvine, US
Somasekhar Bhamidipati · Foster City, US
Catherine Sylvain · Burlingame, US
Hui Li · Santa Clara, US
Alexander B. Rossi · Reedsport, US

Key dates

Filing date	Aug 7, 2013
Grant date	Sep 2, 2014
Priority date	—
Expiry date	Aug 7, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F5/027
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.